GLP-1 Market
LLY $1364.73 ▼ -3.8% NVO $40.30 ▼ -4.5% PFE $29.88 ▼ -3.0% VKTX $25.79 ▼ -7.8% KLRA $12.17 ▼ -4.9% GPCR $19.08 ▼ -6.3% RHHBY $59.45 ▼ -2.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

multiple-dose of Chiglitazar/Metformin

Company
Chipscreen Biosciences, Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 6, 2026

Trial details
  • Completed NCT NCT07511010

    Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets

    Not yet reported Chipscreen Biosciences, Ltd. 28 participants Est. completion 2026-10-25 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: multiple-dose of Chiglitazar/Metformin, multiple-dose of Chiglitazar/Metformin extended-release tablets

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.